Reckitt Benckiser

Reckitt CEO stands by Mead Johnson deal, despite Pfizer option

Sat, 10 Mar 2018 - 09:54 GMT

Reckitt Benckiser has no regrets about its $17 billion acquisition of Mead Johnson last year, its chief executive said.

More